Research Areas

Wyeth Pharmaceuticals and the Health Ministry of Scotland announced recently the creation of the Translational Medicine Research Collaboration (TMRC), an effort into which Wyeth is investing nearly $58.5 million.

Biomedical imaging in playing an increasingly larger role in drug discovery. Ultrasonics, however, still brings to mind images of pregnant mothers and unborn babies. Toronto-based VisualSonics is hoping to change that impression. Recently, Executive Editor Randall C Willis spoke with VisualSonics President and CEO Tom Little.

The cash keeps flowing for the dominant players in developing RNAi therapies, as evidenced recently by a multi-year strategic alliance between pharma giant GlaxoSmithKline and siRNA specialist Sirna Therapeutics Inc. that has the potential to pump more than $700 million into Sirna coffers.

After a string of acquisition including Innovata’s gene expression technology and the companies LINCO and Cytomyx, Atlanta-based Serologicals Corp. is itself being acquired by Millipore Corp. in a $1.4 billion deal.

As mouse models of human disease become more important in drug discovery,

Key to cell biology is the ability to introduce exogenous DNA into cells, but physicochemical methods such as transfection or electroporation often exhibit low efficiencies and can lead to cell damage.

Further expanding commercialization of European products

The Fine Chemicals division of Sigma-Aldrich (SAFC)

Bioinformatics specialist DNASTAR